F. Canducci, B. Barda, E. Ceresola, V. Spagnuolo, M. Sampaolo, E

Slides:

Advertisements

Similar presentations

1 Review of Antiretroviral Therapy in Adults HAIVN Harvard Medical School AIDS Initiative in Vietnam.

Advertisements

1 Introduction to ARV Therapy HAIVN Harvard Medical School AIDS Initiative in Vietnam.

Antiretroviral targets in the viral life cycle Viral Replication and Drug targets.

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

ART 101 Successful HIV treatment usually consists of at least three drugs from two different “classes” of ARV drugs There are now six classes of ARV drugs:

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

Clinical and virologic follow-up in perinatally HIV-1-infected children and adolescents in Madrid with triple-class antiretroviral drug-resistant viruses

R. Cavallo Clinical Microbiology and Infection

L. Boyanova Clinical Microbiology and Infection

Gut bacterial microbiota and obesity

Salvage therapy for multidrug-resistant tuberculosis

Approach to diagnosis of infective endocarditis

Prevalence of etravirine (ETR)-RAMs at NNRTI failure and predictors of resistance to ETR in a large Italian resistance database (ARCA)† S. Rusconi, F.

Molecular characterization of methicillin-resistant Staphylococcus aureus isolated over a 2-year period in a Qatari hospital from multinational patients

Migrant health—a cause for concern?

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

Gastroenteritis outbreak caused by norovirus associated with the children's club of a hotel located in Majorca, Spain A. Doménech-Sánchez Clinical Microbiology.

J.-P. Van geertruyden Clinical Microbiology and Infection

Virological tools to diagnose and monitor hepatitis C virus infection

R. Cantón Clinical Microbiology and Infection

Outwitting Evolution: Fighting Drug-Resistant TB, Malaria, and HIV

Louis Pasteur, from crystals of life to vaccination

How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development R. Bax Clinical Microbiology.

Chlamydia trachomatis infections in heterosexuals attending sexually transmitted disease clinics in Slovenia D. Kese, M. Maticic, M. Potocnik Clinical.

An eye-catching acanthocephalan

Should standardized susceptibility testing for microbial biofilms be introduced in clinical practice? T. Coenye, D. Goeres, F. Van Bambeke, T. Bjarnsholt

Maraviroc 150 mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients:

Vector control: a cornerstone in the malaria elimination campaign

Antiretroviral therapy for initial human immunodeficiency virus/AIDS treatment: critical appraisal of the evidence from over 100 randomized trials and.

Training for the infectious diseases speciality in Norway

F. Grill, P. Muñoz, R. Jofre, E. Bouza

CMI editorial report 2011 Clinical Microbiology and Infection

S. Borrell, S. Gagneux Clinical Microbiology and Infection

Salvage therapy for multidrug-resistant tuberculosis

Elements of design: the knowledge on which we build

Levofloxacin in the treatment of ventilator-associated pneumonia

Metagenomics and probiotics

Laboratory diagnosis of Clostridium difficile disease

Recent developments in staphylococcal scalded skin syndrome

The practice of travel medicine in Europe

T.M. File Clinical Microbiology and Infection

Systematic review of antibiotic consumption in acute care hospitals

Update on antifungal resistance in Aspergillus and Candida

Harmonised monitoring of antimicrobial resistance in Salmonella and Campylobacter isolates from food animals in the European Union S. Bronzwaer Clinical.

Abstracts cont. Clinical Microbiology and Infection

Pandemic lineages of extraintestinal pathogenic Escherichia coli

Virological rebound in human immunodeficiency virus-infected patients with or without residual viraemia: results from an extended follow-up N. Gianotti,

Tuberculosis transmission patterns among Spanish-born and foreign-born populations in the city of Barcelona S. Borrell, G. Tudó, E. Rey, J. González-Martín

Current experience in treating invasive zygomycosis with posaconazole

H. Leblebicioglu, C. Eroglu Clinical Microbiology and Infection

An after-hours clinical liaison blood culture service—is it worth it?

Statin use and clinical outcomes among pneumonia patients

Clinical Microbiology and Infection

Changing pattern of candidaemia 2001–2006 and use of antifungal therapy at the University Hospital of Vienna, Austria E. Presterl, F. Daxböck, W. Graninger,

HIV DNA loads, plasma residual viraemia and risk of virological rebound in heavily treated, virologically suppressed HIV-infected patients N. Gianotti,

W. Eugene Sanders, Christine C. Sanders

K. Kaier, N.T. Mutters, U. Frank Clinical Microbiology and Infection

The atypical pneumonias: clinical diagnosis and importance

J.J. Keller, M.-C. Tsai, C.-C. Lin, Y.-C. Lin, H.-C. Lin

Abstracts Clinical Microbiology and Infection

Virology: a scientific discipline facing new challenges

Modelling during an emergency: the 2009 H1N1 influenza pandemic

B.A. Cunha Clinical Microbiology and Infection

J.L. Balcázar Clinical Microbiology and Infection

G.C. Schito Clinical Microbiology and Infection

New patterns of HIV-1 resistance during HAART

Impact of antibiotic restrictions: the patient's perspective

Comparative study of pediculicidal effect of medical plants

CMI readers' survey Clinical Microbiology and Infection

The future of diagnostic bacteriology

Presentation transcript:

Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption F. Canducci, B. Barda, E. Ceresola, V. Spagnuolo, M. Sampaolo, E. Boeri, S. Nozza, F. Cossarin, A. Galli, N. Gianotti, A. Castagna, A. Lazzarin, M. Clementi Clinical Microbiology and Infection Volume 17, Issue 6, Pages 928-934 (June 2011) DOI: 10.1111/j.1469-0691.2010.03375.x Copyright © 2011 European Society of Clinical Infectious Diseases Terms and Conditions

FIG. 1 Virological and immunological parameters of the patients described in the study and patients’ therapies. AZT, zidovudine; FTC, emtricitabine; TdF, tenofovir; RAL, raltegravir; ETR, etravirine; 3TC, lamivudine; DRV, darunavir; ENF, enfuvirtide; MVC, maraviroc; ABC, abacavir; f-APV, fosamprenavir; LPV/r, lopinavir/ritonavir; DRV/r, darunavir/ritonavir; TPVr, tipranavir/ritonavir. Clinical Microbiology and Infection 2011 17, 928-934DOI: (10.1111/j.1469-0691.2010.03375.x) Copyright © 2011 European Society of Clinical Infectious Diseases Terms and Conditions